The Race To Cure Alzheimer's: Breakthrough or False Dawn?

The Question

Here is the specific thing we are predicting: will a drug that genuinely halts Alzheimer's disease — stops it in its tracks — receive regulatory approval by 2035? Our model says 44% probability. That is nearly a coin flip, and deliberately so. The question matters because two drugs, lecanemab and donanemab, were approved by the FDA in 2023 and 2024. For the first time in history, after more than 200 failed trials, we have medicines that demonstrably change the course of Alzheimer's. That is a real milestone. But "27% slower decline over 18 months" is not the same as stopping the disease. The next decade will tell us whether these approvals were the first step toward a cure or the ceiling we were always heading for.

Alzheimer's has beaten medicine for decades. The reason is brutally simple: the disease starts damaging the brain 15 to 20 years before any symptoms appear, and by the time you forget your keys regularly, enormous damage has already been done. Earlier drugs failed because they couldn't clear the sticky protein clusters — called amyloid plaques — that build up in the brain. Lecanemab and donanemab can clear them. That is why they work, at least partially. The question is what comes next.

What the Evidence Shows

The current drugs work by targeting amyloid — a protein that clumps into plaques between brain cells. Clear the plaques and you slow the disease. It sounds straightforward, but it took 30 years and hundreds of failed attempts to get here. The new drugs work. They just don't work enough. A 27% slowing of decline is real, but it still means decline. Researchers are now turning to the next target: tau protein, which forms tangled knots inside brain cells (called neurofibrillary tangles) and correlates even more closely with how much memory and thinking ability a patient loses. Anti-tau drugs are already in late-stage clinical trials. The hypothesis is that combining amyloid-clearing drugs with tau-targeting drugs could stop the disease rather than slow it.

The single most exciting development right now isn't a drug at all. It is a blood test. A simple blood test called p-tau217 can now detect Alzheimer's damage in the blood with 90% accuracy — years before any symptoms appear. Think about what that means. The drugs we have work best in early disease. If you can identify people who are heading toward Alzheimer's a decade before they notice anything, you can treat them early enough to actually prevent the worst. The blood test costs around $200. The problem is that most health systems aren't yet set up to act on the result.

Why This Is Happening

The numbers are staggering. Fifty-five million people worldwide live with dementia today. By 2050, that figure is projected to reach 153 million. Most of the cost — financial and human — falls on family caregivers, predominantly women, who provide unpaid care for years. No health system in the world is currently equipped to manage this at scale. That pressure is a large part of why research funding has accelerated so dramatically.

Lifestyle matters more than most people think. Research from the Lancet Commission on Dementia Prevention has identified twelve lifestyle factors — high blood pressure, obesity, smoking, physical inactivity, depression, social isolation, hearing loss, and others — that together account for roughly 40% of all dementia cases. Exercise has the strongest prevention evidence of anything currently known, improving blood flow to the brain and stimulating chemicals that help brain cells survive. Sleep matters too: the brain's waste-clearance system flushes out amyloid and tau during sleep, and chronic poor sleep may be quietly accelerating Alzheimer's pathology in millions of people.

Cost is already a crisis. Lecanemab costs $26,500 a year. Medicare in the US covers it, but with significant administrative barriers that make access difficult in practice. Europe's drug regulator initially declined to approve it, arguing the modest benefit didn't outweigh the risks — which include brain swelling and small bleeds in some patients. The result is a drug that exists, works partially, and remains out of reach for most people who could benefit from it.

What Could Happen

What Can We Do

You don't need to wait for a drug approval to reduce your risk. Regular aerobic exercise — 150 minutes a week of moderate effort — is associated with a 35% reduction in dementia risk in large studies, a bigger effect than most drugs currently in trials. Controlling blood pressure, keeping a healthy weight, not smoking, and staying socially connected all chip away at the same risk. None of these are guarantees. But they are real, free, and available right now.

Health systems have a different job: build the infrastructure that the new testing era demands. The p-tau217 blood test is cheap — about $200 — and can identify Alzheimer's damage in the blood years before symptoms. But a positive test result is only useful if there are memory clinics, trained specialists, and reimbursed treatments waiting at the end of the referral pathway. Most health systems don't have that yet. Building it now — before the next wave of drugs arrives — is the smartest move policymakers could make.

For researchers and funders, the case for sustained investment has never been stronger. The NIH Alzheimer's budget grew from $631 million in 2015 to over $3.7 billion in 2024, and the first disease-modifying drugs vindicate that spending. The next phase — combination therapies, prevention trials, gene-based approaches targeting the APOE4 risk gene — needs that funding to continue. This is not the moment to slow down.